DBV Technologies Initiates Phase I/II Clinical Trial with

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
DBV Technologies Initiates Phase I/II Clinical Trial with Viaskin Milk for the Treatment of Children with Cow's Milk Allergy

BAGNEUX, France, Nov. 20, 2014 (GLOBE NEWSWIRE) -- DBV Technologies, (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), a clinical-stage specialty biopharmaceutical company, announced today it has begun enrolling cow's milk-allergic subjects in a Phase I/II clinical study to evaluate the safety and efficacy of Viaskin® Milk, an epicutanous patch for the treatment of children with IgE-mediated cow's milk allergy (CMA).

Pierre-Henri Benhamou , M.D., Chairman and CEO of DBV Technologies said: "Milk allergy is a life-threatening condition for which there are no approved treatments. As part of our commitment to improve the quality of life of food allergic patients, we have continued to advance our pipeline, and the initiation of this trial marks an important milestone for our patients, their caretakers and our Company. We believe Viaskin has the potential to reshape the future of food allergies immunotherapy."

The Viaskin MIL k E fficacy and S afety Phase I/II study, or MILES study, is a multi-center, double-blind, placebo-controlled, randomized study designed to evaluate the safety and efficacy of Viaskin® Milk used to treat subjects on a daily basis by Epicutaneous Immunotherapy (EPIT®). Eligible subjects are those with elevated cow's milk-specific Immunoglobulin E levels and who show clear objective signs or symptoms to an eliciting dose of cow's milk proteins less or equal to 300 mg (approximately 9.4 mL of cow's milk.

The MILES study is composed of 2 parts. Part A, or Phase I, will evaluate the safety of three escalating doses of Viaskin® Milk (150 microgram, 300 microgram and 500 microgram cow's milk protein) versus placebo over three weeks. Part B, or Phase II, will evaluate the efficacy and safety of up to 12 months of EPIT with two selected doses of Viaskin® Milk from Part A. Approximately 150 subjects (18 subjects in Part A and 132 subjects in Part B) from 2 to 17 years of age will be randomized in the study, at selected North American sites, specialized in the management of food allergic subjects.

The primary efficacy endpoint is the percentage of treatment responders after 12 months of EPIT. Responders are subjects who meet one of the following criteria: a higher or equal to a 10-fold increase in the cumulative reactive dose (CRD) of cow's milk proteins at the Month 12 food challenge as compared to the baseline value and reaching at least 144 mg of cow's milk proteins (approximately 4.5 mL of milk); or a CRD of cow's milk proteins higher or equal to 1444 mg (approximately 45 mL of milk) at the Month 12 food challenge.

Bpifrance will be providing €3 million in the form of an interest free loan (PTZI: Prêt à Taux Zero pour l'innovation) to DBV for the clinical development of Viaskin® Milk. This funding demonstrates Bpifrance's continued support for DBVs development programs. The interest-free loan provided by Bpifrance has a first date of payment as of June 30, 2017. After this initial payment, 19 linear quarterly payments will follow until March 31, 2022.

About Viaskin® Milk

Viaskin Milk for the treatment of pediatric CMA is DBV's second most advanced product in development. CMA is the first allergy to appear during early childhood and the most common food allergy in infants and young children, affecting 2% to 3% of the general population. CMA is often missed in the primary care setting and can be a significant cause of infant distress when left undiagnosed. Symptoms can include gastrointestinal problems including vomiting and diarrhea, skin rash, angioedema or rapid swelling of the skin, and anaphylaxis. The only option available for CMA management is the avoidance of cow's milk, which can lead to issues of dietary imbalance, failure to thrive and poor quality of life.

About DBV Technologies

DBV Technologies is developing Viaskin®, an innovative new approach to the treatment of allergies - a major public health issue that has been increasing in prevalence. DBV Technologies, incorporated in France in 2002, has developed a proprietary, worldwide-patented technology for administering an allergen to intact skin while avoiding transfer to the blood, and thus considerably lowering the risk of a systemic, allergic reaction in the event of accidental exposure. DBV Technologies is focusing on food allergies, including milk and peanut, for which there are currently no effective treatments. DBV Technologies has designed two products candidates: Viaskin® Peanut and Viaskin® Milk. The clinical development program for Viaskin® Peanut has received Fast Track designation from the US Food and Drug Administration.

DBV Technologies shares are traded on segment C of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345) and on the Nasdaq Stock Market in the form of American Depositary Shares (each representing one-half of one ordinary share) (Ticker: DBVT).

For more information on DBV Technologies, please visit our website: www.dbv-technologies.com   

About Bpifrance

Formed by the law of the 31st December 2012, Bpifrance (a public sector investment bank) is the outcome of the merger between OSEO, the FSI, CDC Entreprises and FSI Régions. Its two shareholders are the French state and the Caisse des Dépôts bank. Bpifrance finances businesses from the seed phase to transfer to stock exchange listing, through loans, guarantees and equity. Bpifrance also provides enhanced support and backing for innovation, export, and external growth. With its 42 regional offices, it is a one-stop shop for entrepreneurs in each region for all their finance and investment needs. Bpifrance also participates in the management of several European funding programs. www.bpifrance.fr - Follow us on Twitter: @bpifrance  

Forward Looking Statements

This press release contains forward-looking statements, including statements about the safety and efficacy of DBV Technologies' product, our ability to successfully complete the clinical trial, our ability to obtain regulatory approval for and commercialize Viaskin® Milk, and our ability to obtain funding from Bpifrance.  These forward-looking statements are not promises or guarantees and involve substantial risks and uncertainties. Among the factors that could cause actual results to differ materially from those described or projected herein include uncertainties associated generally with research and development, clinical trials and related regulatory reviews and approvals, the risk that historical clinical trial results may not be predictive of future trial results, whether Viaskin® Milk will be successfully marketed if approved, and subsequent changes in the agreement with Bpifrance.  A further list and description of these risks, uncertainties and other risks can be found in the Company's regulatory filings with the French Autorité des Marchés Financiers, the Company's Securities and Exchange Commission filings and reports, including in the Company's prospectus filed with the SEC on October 22, 2014 and future filings and reports by the Company.  Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. DBV Technologies undertakes no obligation to update or revise the information contained in this Press Release, whether as a result of new information, future events or circumstances or otherwise.   

DBV Technologies Contacts

David Schilansky
Chief Financial Officer
Tel. : +33(0)1 55 42 78 75
david.schilansky@dbv-technologies.com

 

Susanna Mesa
VP Finance, US Investor Relations & Strategy
Tel. : +1 917-346-3447
susanna.mesa@dbv-technologies.com

DBV IR and Media Contacts

Nathalie Donne
Director, Corporate Communication & Business Development
Tel. : +33(0)1 55 42 78 72
nathalie.donne@dbv-technologies.com

Todd James
U.S. Investor Relations
The Trout Group
Tel. : +1 646-378-2926
tjames@troutgroup.com
Rooney & Associates
Media Relations
Marion Janic
Tel. : +1-212-223-4017
mjanic@rooneyco.com

DBV Initiates Phase I/II Clinical Trial with Viaskin Milk http://hugin.info/156437/R/1872841/659417.pdf

HUG#1872841

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Linkind's Best Buy Push Tests Smart Outdoor Demand

Updated Category News Views 199

Holiday lights have quietly become a year-round hardware category, and Linkind wants a louder seat at the table. The smart-lighting brand says three outdoor products have been in Best Buy stores across the United States since October 17, 2026: permanent exterior lights, decorative string lights, and solar pathway lights. That is a real distribution step, not some grand...

Continue Reading
Swell Partners' Awards Highlight Culture, Not Metrics

Updated Category News Views 26

Recognition Lands in a Crowded Talent Market Two shiny Stevie trophies do not pay payroll, but they can say something useful about a company trying to stand out in the noisy talent-services business. Swell Partners has been named 2026 Company of the Year in Business Services and has seen founder and CEO Cari Gatto receive Best Female CEO of the Year. For a private firm...

Continue Reading
Sokin’s UAE License Turns Expansion Into Real Payments Plumbing

Updated Category News Views 118

Dubai expansion headlines are cheap; regulated local money movement is not. That is why Sokin’s newly approved Dubai Financial Services Authority license deserves more than the usual fintech applause line. The company has paired that approval with AED accounts, local payment rails, a One Za’abeel office and a plan to double its UAE staff over the next year. None of...

Continue Reading
MetaOptics Tests a Real Path Into Secure Imaging Markets

Updated Category News Views 68

Fingerprint scanners have never impressed me much; fooling one is exactly the sort of nuisance that keeps security buyers spending. MetaOptics’ new collaboration with Hong Kong’s ASTRI goes after that uncomfortable problem with a compact nano-optics imaging system built for biometric security and smart sensing. It is a sensible target. It is also, at this stage, a...

Continue Reading
MetaComp's $10M Extension Tests Stablecoin Rails in Trade

Updated Category News Views 21

A ten-million-dollar check is cheap until the licensing bills start arriving. MetaComp has added roughly US$10 million from Tether and Abu Dhabi-based Further Asset Management, taking its Pre-A and Pre-A+ fundraising to about US$45 million. The important bit is not the headline-sized pile of cash. It is where management says the money is going: licences, compliance...

Continue Reading
Esquire Spotlight Puts Trauma Cleanup Work in Focus

Updated Category News Views 88

A national magazine profile is an odd milestone for a business built around other people’s worst days. David Lesaffre, co-owner and operator of T.A.C.T. 48, T.A.C.T. AZ, and T.A.C.T. Fort Worth, has been featured by Esquire in a piece called “The Trauma Cleaners.” The attention is deserved, frankly, because biohazard remediation is one of those necessary services...

Continue Reading
Hagerty's Fifth Film Win Keeps Its Media Engine Humming

Updated Category News Views 57

A lap record, a camera crew, and five straight trophies make a louder statement than another glossy corporate slogan. Hagerty won Best Journalism Film at the 2026 International Motor Film Awards on Nov. 14, held at the Petersen Automotive Museum in Los Angeles. The company has taken that particular award home five years running, powered again by Jason Cammisa and his...

Continue Reading
Housing's Value Equation Is Getting More Complicated

Updated Category News Views 82

A homeowner's insurance bill has become a louder market signal than a granite countertop. Green Builder Media's latest batch of research, publishing and events is aimed squarely at that uncomfortable truth: housing is no longer judged only by the price on the contract. Buyers, builders, lenders and insurers are being pushed to reckon with what a home costs to own, protect...

Continue Reading
HiTHIUM's 8-Hour Storage Pitch Faces Real Grid Tests

Updated Category News Views 61

Eight hours of stored electricity is where the sales brochure meets the ugly parts of the grid. HiTHIUM arrived at RE+ 2026 in Las Vegas, held November 17 through 19, with a broad storage pitch: systems ranging from two to eight hours, lithium-ion and sodium-ion chemistry, plus the software and validation work needed to make a battery plant behave when the local grid gets...

Continue Reading
LevelTen Takes Its Clean-Power Market Model to India

Updated Category News Views 50

India's power market is not a tidy spreadsheet, thankfully. It is a vast, fast-growing grid where data centres, factories and climate exposure are all colliding with a generation mix still dominated by coal. That is why LevelTen Energy's move into Asia-Pacific deserves more than the usual clean-tech applause line. Beginning with a 500 MW clean-energy request for proposals...

Continue Reading

Top 5 Most Recently Viewed Articles

Private Tutoring Insights: Learning from Finland's Education Method

Updated Category News Views 206

Exploring Finland's Educational Principles for Private Tutoring In today's rapidly evolving educational landscape, Tutors International passionately investigates various global education models. One system that stands out is Finland's renowned educational approach, widely admired for its emphasis on holistic learning and well-being. Tutors International's latest analysis...

Continue Reading
Charter Communications and Cox Communications Join Forces

Updated Category News Views 162

Charter Communications Merges with Cox Communications In a pivotal move for the telecommunications industry, Charter Communications and Cox Communications have entered into a definitive agreement to combine their companies. This merger signifies a significant consolidation within the sector, promising advancements in service delivery and enhanced operational efficiency...

Continue Reading
Investor Insights on Dyne Therapeutics: Understanding Risks

Updated Category News Views 568

Understanding the Current Situation of Dyne Therapeutics Dyne Therapeutics, Inc. (NASDAQ: DYN) is currently under scrutiny as Pomerantz LLP investigates potential claims on behalf of investors. The concerns arise regarding whether Dyne and its executives may have engaged in improper securities practices. Investors holding shares or contemplating an entry into the market...

Continue Reading
Scientology's New Campaign Aims to Inspire Global Engagement

Updated Category News Views 116

Scientology Launches Global Welcome Campaign The Church of Scientology International is excited to unveil its innovative Global Welcome to Scientology campaign. This initiative is a powerful effort focused on bringing people together and elevating the human experience through understanding and discovery. Inspiring Discovery Across the Globe With the aim of fostering a...

Continue Reading
Deborah R. Willig Shines in Lawdragon's Prestigious Award List

Updated Category News Views 241

Deborah R. Willig Recognized Among Leading Civil Rights Attorneys Willig, Williams & Davidson proudly announces that Deborah R. Willig, the firm's managing partner, has once again earned a spot in the esteemed Lawdragon 500 list of leading civil rights and plaintiff employment lawyers. This recognition underscores her unwavering commitment to advocating for workers'...

Continue Reading